The Journal of surgical research · 2025
Comparison of Short-Term Quality of Life Between Subxiphoid and Lateral Intercostal Approaches Thoracoscopic Thymectomy for Nonmyasthenic Early-Stage Thymoma: A Prospective Study.
СтатьяСравнительное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Ming-Sheng, Yang Jian-Fei, Wang Gao-Xiang, Chen Zheng-Wei, Huang Zhi-Ning, Cui Shi-Jun, Chen Xiao, Xie Ming-Ran
Аннотация
INTRODUCTION: To compare the short-term outcomes and postoperative quality of life of patients with nonmyasthenic early-stage thymoma who underwent subxiphoid approach to video-assisted thoracic surgery (S-VATS) or lateral intercostal approach VATS (L-VATS).
METHODS: A prospective, nonrandomized study was conducted. From July 2020 to June 2022, 60 patients with nonmyasthenic early-stage thymoma were enrolled and divided into two groups: 30 received S-VATS and 30 received L-VATS. The Quality-of-Life Questionnaire-Core 30 scale was used to measure the quality of life of the patients before surgery and at 1, 2, 4, and 8 wk after surgery. Linear mixed-effects models with an interaction term (surgery type × time) were used to test for differences in mean domain scores and differing effects of approach over time, adjusting for baseline scores.
RESULTS: The S-VATS group had less postoperative drainage (P = 0.021), shorter drainage duration (P = 0.12), and shorter postoperative hospital stay (P = 0.006) than the L-VATS. The quality-of-life dimensions of the two groups were similar before surgery, but they changed after surgery: the functional domains and general health status decreased, while the symptomatic domains increased. The S-VATS group had higher scores in global health status (difference 4.9; 95% confidence interval [CI] 2.0, 7.8; P < 0.01), physical functioning (difference 4.5; 95% CI 1.8, 7.2; P < 0.01), emotional functioning (difference 3.5; 95% CI 1.7, 5.3; P < 0.01), social functioning (difference 6.9; 95% CI 3.4, 10.5; P < 0.01), and lower scores in fatigue (difference -3.6; 95% CI -5.2, -2.0; P < 0.01), pain (difference -6.7; 95% CI -8.9, -4.4; P < 0.01).
CONCLUSIONS: S-VATS is an effective treatment for patients with nonmyasthenic early-stage thymoma, and it can significantly improve perioperative outcomes and the postoperative quality of life.
METHODS: A prospective, nonrandomized study was conducted. From July 2020 to June 2022, 60 patients with nonmyasthenic early-stage thymoma were enrolled and divided into two groups: 30 received S-VATS and 30 received L-VATS. The Quality-of-Life Questionnaire-Core 30 scale was used to measure the quality of life of the patients before surgery and at 1, 2, 4, and 8 wk after surgery. Linear mixed-effects models with an interaction term (surgery type × time) were used to test for differences in mean domain scores and differing effects of approach over time, adjusting for baseline scores.
RESULTS: The S-VATS group had less postoperative drainage (P = 0.021), shorter drainage duration (P = 0.12), and shorter postoperative hospital stay (P = 0.006) than the L-VATS. The quality-of-life dimensions of the two groups were similar before surgery, but they changed after surgery: the functional domains and general health status decreased, while the symptomatic domains increased. The S-VATS group had higher scores in global health status (difference 4.9; 95% confidence interval [CI] 2.0, 7.8; P < 0.01), physical functioning (difference 4.5; 95% CI 1.8, 7.2; P < 0.01), emotional functioning (difference 3.5; 95% CI 1.7, 5.3; P < 0.01), social functioning (difference 6.9; 95% CI 3.4, 10.5; P < 0.01), and lower scores in fatigue (difference -3.6; 95% CI -5.2, -2.0; P < 0.01), pain (difference -6.7; 95% CI -8.9, -4.4; P < 0.01).
CONCLUSIONS: S-VATS is an effective treatment for patients with nonmyasthenic early-stage thymoma, and it can significantly improve perioperative outcomes and the postoperative quality of life.